“20/20 Hindsight” Platform Improves Accuracy of Most Widely Used Cancer Biomarkers 20/20 GeneSystems, Inc. is a Rockville, MD-based, digital diagnostics company focused on reducing cancer mortality through early detection. 20/20 GeneSystems is […]
Q1© Platform Takes Unique Approach to Isolation and Interrogation of Individual Cancer Cells QuantumCyte is a Silicon Valley-based early-stage biotechnology company that is developing a unique drug assay system. QuantumCyte’s single-cell analysis […]
After graduating from Cornell, William Werkmeister started his career as an investment banker at Salomon Smith Barney and Citigroup and then worked for a series of state-sponsored venture capital funds that supported […]
CAR T Cell Therapy May Change Cancer Patients’ Own Weak T Cells into “Bionic Killing Machines” Aurora Biopharma is a Cambridge, MA-based, clinical-stage company that is developing state-of-the-art cancer immunotherapy, utilizing a […]
Phil Polakoff who has been engaged in the healthcare field for over 35 years, offers a unique perspective on where we are and where we are going. Brett Johnson: Phil, what do […]
Company Successfully Transfers T-Cell Receptor Genetic Material into Human Hematopoietic Stem Cells ImmunoCellular Therapeutics, Ltd., a Los Angeles-based clinical stage immuno-oncology company, has achieved an important milestone toward initiating pre-clinical trials of […]
TRE-515 Therapy Targets Multiple Pathways to Improve Treatment Efficacy Over Single-Agent Approaches Trethera Corporation, a Los Angeles-based clinical-stage biopharmaceutical company, is developing cancer treatments for orphan blood cancers with high unmet needs. […]
Targeted DiversiTy™ Therapy Promotes Surveillance and Destruction of Cancer Cells By Re-Educating Patients’ Own T Cells Geneius is an immuno-oncology company based in Natick, MA, that is focused on T-cell immunotherapies for […]
